BEAM

Beam Therapeutics
BEAM

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$1.66B
EV
$661.41M
Shares Outstanding
98.28M
Beta
2.22

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$45.92
P/E 2025E
-
P/Revenue 2025E
35.37x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Beam Therapeutics Inc.

gainify
BEAM

Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-30...

Sector

Healthcare

Industry

Biotechnology

CEO

Evans, John

Employees

509

Website

beamtx.com

IPO Date

2020-02-06

Headquarters

238 Main Street, 9th Floor, Cambridge, Massachusetts, 02142-1016, United States

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.